 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on...

Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Buy

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBA Research Report) and Precision BioSciences...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) had its target price boosted by HC Wainwright from $5.00 to $6.00 in a research note issued on Thursday, Benzinga reports. The firm currently has...

Akebia Therapeutics (NASDAQ:AKBA) PT Raised to $6.00 at HC Wainwright

Akebia Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis Akebia Receives FDA Approval of Vafseo (vadadustat...

Akebia Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Akebia Therapeutics (AKBA) has provided an update. Akebia Therapeutics, Inc. has made a significant stride in the healthcare market with the FDA's...

Akebia Therapeutics Celebrates FDA Approval of Anemia Drug

Akebia Therapeutics (NASDAQ:AKBA  Get Free Report) had its price target boosted by analysts at HC Wainwright from $5.00 to $6.00 in a research report issued on Thursday, Benzinga reports. The...

Akebia Therapeutics (NASDAQ:AKBA) Price Target Raised to $6.00

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval...

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Akebia Therapeutics, Inc. (NASDAQ:AKBA  Get Free Report) saw some unusual options trading activity on Tuesday. Investors acquired 2,369 put options on the company. This represents an increase...

Akebia Therapeutics Sees Unusually High Options Volume (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA  Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting...

Akebia Therapeutics (NASDAQ:AKBA) Announces  Earnings Results, Meets Estimates

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Volume (M)	2.94M
52-Wk High	$2.48
52-Wk Low	$0.5895

AKBA Akebia Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals